Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 4Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia 2Rectal Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Congenital Abnormalities 1Colorectal Neoplasms 1Colonic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 11tipifarnib 4Idarubicin 4Etoposide 4Sorafenib 3Bortezomib 3tanespimycin 2laromustine 2alvocidib 2Peripheral Blood Stem Cell Transplantation 2Mitoxantrone 2Gene Expression Profiling 2Daunorubicin 2DNA Methylation 2Busulfan 2Azacitidine 2valspodar 1romidepsin 1ixabepilone 1fludarabine phosphate 1entinostat 1aldesleukin 1XK 469 1Watchful Waiting 1Vorinostat 1Observation 1Microarray Analysis 1Melphalan 1Lenalidomide 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Eosinophilic, Acute × Cytogenetic Analysis × Clear all
NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡